NCT05979493 QL Block in Laparoscopic Myomectomy
| NCT ID | NCT05979493 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Joseph Findley MD |
| Condition | Postoperative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-08-24 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2024-08-24 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to determine the efficacy of a quadratus lumborum (QL) block in decreasing postoperative pain in patients undergoing myomectomy for uterine fibroids. A QL block is a temporary anesthetic injection in the quadratus lumborum muscle, a muscle in the lower back, that has been previously shown to significantly reduce postoperative pain levels in patients undergoing abdominal and pelvic surgery. Because of its demonstrated effects, the QL block is becoming a standard of anesthesia and surgical care. Since participants will be undergoing a myomectomy procedure, the investigators believe that participants may qualify to participate in this study. The investigators will be comparing patients who receive the QL block (in addition to standard anesthesia and postoperative pain care) with patients who do not receive the QL block (in addition to standard care). The participants will be randomly assigned to one of the two groups and may or may not actually receive the block.
Eligibility Criteria
Inclusion Criteria: * Presence of uterine fibroids requiring surgical excision with preservation of the uterus * Stated willingness to comply with all study procedures and availability for the duration of the study * Provision of signed and dated informed consent form Exclusion Criteria: * Pre-existing diagnoses of anxiety or depression * Pre-existing coagulopathies * Pre-existing neuropathic or chronic pelvic pain * Chronic opioid use * Illiteracy due to inability to read and understand plain questionnaire * Non-English speaking * BMI \>38
Contact & Investigator
Joseph Findley, MD
PRINCIPAL INVESTIGATOR
University Hospitals
Frequently Asked Questions
Who can join the NCT05979493 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05979493 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05979493 currently recruiting?
Yes, NCT05979493 is actively recruiting participants. Contact the research team at cph43@case.edu for enrollment information.
Where is the NCT05979493 trial being conducted?
This trial is being conducted at Beachwood, United States.
Who is sponsoring the NCT05979493 clinical trial?
NCT05979493 is sponsored by Joseph Findley MD. The principal investigator is Joseph Findley, MD at University Hospitals. The trial plans to enroll 80 participants.